A story from Bioness
“This gives us something we've never had before: objective gait data beyond 'improved toe clearance.'”
Natalie Gay, Bioness Medical
Bioness reps knew the L300 Go improved gait for people with foot drop. They could see it. Therapists could see it. Payers wanted something they could read.
Screening-day trials produced a demonstration, not data. Without objective before-and-after measurement, clinical conversations leaned on "improved toe clearance," configuration upgrades were hard to justify, and letters of medical necessity had little to stand on.
Patients walk with a phone in a pocket before and after putting on the device. OneStep returns 30+ gait parameters and a walk score in minutes — for the therapist, the physician, the payer and the rep. Across 230 patients, both the L300 Go and the Go Plus showed statistically significant gains in walking speed, stride length and overall walk score on the very first trial, with the typical patient gaining 6 cm of step length.
Screening days with OneStep closed 15.3% more often, 5.4 days faster, and at $423 higher average sale — more bilateral systems and thigh cuffs, because the data made the case. A Medicare Advantage plan reversed a 2023 denial after a letter of medical necessity built on OneStep's patient note. 84% of the sales team say OneStep improved their process.
Every trial is now evidence. Every rep is now credible.